Persistent hypoalbuminemia with intestinal lymphangiectasia and recurrent edema should prompt consideration of CHAPLE disease and genetic confirmation. Early recognition of CD55 deficiency with timely ...

Pemafibrate is being developed for patients with inadequate response or intolerance to ursodeoxycholic acid, as add-on or monotherapy. Pemafibrate (K-808) has been granted Breakthrough Therapy ...

Delegates at ATS 2026 in Orlando, Florida, test their skills at an AI lab (Photo by Larry Luxner) There were more than 20 sessions focused on AI at the 2026 ATS conference, which was attended by ...

Efficacy analyses for the first 2 cohorts of the phase 1/2 studies will compare participant outcomes with those of a propensity score-matched external control group. AMT-130, an investigational gene ...

(Getty Images) Sibeprenlimab also demonstrated a 51.2% placebo-adjusted reduction in 24-hour urine protein-creatinine ratio at 9 months. No patients in the sibeprenlimab arm reached significant ...

An unexpected 64% placebo response rate, likely amplified by oral administration and repeated subjective assessments, may have influenced the results. A phase 2 study of vemircopan in adults with ...

Nephrologist Gates Colbert, MD, speaks at the Renal Physicians Association 2026 Annual Meeting in Atlanta, Georgia (Photo by Riya Ajmera) With 4 pivotal therapy types now available, CKD remission is ...

The model had an area under the receiver operating characteristic curve of 0.83 in a high-risk subgroup of patients with conditions that mimic ATTR-CM. An artificial intelligence model trained to ...

Lower rates of chronic and acute GVHD, infections, and nonrelapse mortality indicate a substantially reduced toxicity burden. In patients with myelodysplastic syndrome (MDS) and acute leukemias ...

The study's outcomes revealed durable improvements, including composite biochemical response, liver stiffness separation from placebo, albumin enhancements, and UK-PBC score benefits. The nanoparticle ...

Rh immunoglobulin is recommended only after small-volume (ie, ≤1 unit) RhD-positive low-titer group O whole blood or RBC transfusions in RhD-negative females of childbearing potential, with ...

The CAPTIVATE trial met its target of at least 20 responders among the first 40 participants before all 40 completed part A. Dianthus Therapeutics announced an early “go” decision for claseprubart for ...